Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression

Aly-Khan A. Lalani; Kathryn P. Gray; Laurence Albiges; Marcella Callea; Jean-Christophe Pignon; Soumitro Pal; Mamta Gupta; Rupal S. Bhatt; David F. McDermott; Michael B. Atkins; G.F. Vande Woude; Lauren C. Harshman; Toni K. Choueiri; Sabina Signoretti

doi:10.18632/oncotarget.21952

journal article Oct 23, 2017

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression

Aly-Khan A. Lalani Kathryn P. Gray Laurence Albiges

Marcella Callea Jean-Christophe Pignon Soumitro Pal Mamta Gupta

Rupal S. Bhatt

David F. McDermott

Michael B. Atkins

G.F. Vande Woude Lauren C. Harshman Toni K. Choueiri

Sabina Signoretti

Oncotarget Vol. 8 No. 61 pp. 103428-103436 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.21952

Topics

No keywords indexed for this article. Browse by subject →

References

28

[1]

Aaronson "Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product" Science (1991) 10.1126/science.1846706

[2]

Bottaro "Targeting the c-Met signaling pathway in cancer" Clin Cancer Res (2006) 10.1158/1078-0432.ccr-06-0818

[3]

Choueiri "Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma" Cancer J (2013) 10.1097/ppo.0b013e31829e3c9a

[4]

Ke "Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures" PLoS One (2014) 10.1371/journal.pone.0099399

[5]

Bai "High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis" Tumour Biol (2015) 10.1007/s13277-014-2659-5

[6]

Kluger "c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma" Ann Oncol (2013) 10.1093/annonc/mds463

[7]

Bono "Correlation of c-Met expression and outcome in patients with renal cell carcinoma treated with sunitinib" Clin Genitourin Cancer (2017) 10.1016/j.clgc.2017.01.021

[8]

Krieg "Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET" Proc Natl Acad Sci USA (2014) 10.1073/pnas.1404848111

[9]

Kluger "c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma" Ann Oncol (2013) 10.1093/annonc/mds463

[10]

Christensen "HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors" Cancer Res (2010) 10.1158/0008-5472.can-10-0489

[11]

Sircar "Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma" Oncogene (2016) 10.1038/onc.2015.343

[12]

McDonald "Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors" Cancer Discov (2012) 10.1158/2159-8290.cd-11-0240

[13]

Pili "Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models" Mol Cancer Ther (2015) 10.1158/1535-7163.mct-14-0094

[14]

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K Choueiri, Bernard Escudier, Thomas Powles et al.

The Lancet Oncology 2016 10.1016/s1470-2045(16)30107-3

[15]

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al.

New England Journal of Medicine 2015 10.1056/nejmoa1510016

[16]

Morris "Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN trial" J Clin Oncol (2017) 10.1200/jco.2016.70.7398

[17]

Lalive "Hepatocyte growth factor: A regulator of inflammation and autoimmunity" Autoimmun Rev (2015) 10.1016/j.autrev.2014.11.013

[18]

Trepel "Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma" J Clin Oncol (2014)

[19]

Pal "Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 Expression" J Biol Chem (2015) 10.1074/jbc.m114.612689

[20]

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Marco Gerlinger, Andrew J. Rowan, Stuart Horswell et al.

New England Journal of Medicine 2012 10.1056/nejmoa1113205

[21]

Limas "Prognostic significance of morphologic parameters in renal cell carcinoma" Am J Surg Pathol (1982) 10.1097/00000478-198210000-00007

[22]

McDermott "Differential Expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma" Cancer Immunol Res (2015) 10.1158/2326-6066.cir-15-0043

[23]

Heng "Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience" Ther Adv Urol (2016) 10.1177/1756287216663073

[24]

Roth "MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker" Oncotarget (2017) 10.18632/oncotarget.13540

[25]

Jilaveanu "MET expression in primary and metastatic clear cell renal cell carcinoma: implications of correlative biomarker assessment to MET pathway inhibitors" Biomed Res Int (2015)

[26]

Go "Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status" Ann Surg Oncol (2016) 10.1245/s10434-015-4903-7

[27]

Lespagnol "Correlation of c-MET expression with PD-L1 expression in metastatic clear cell renal cell carcinoma treated by sunitinib first-line therapy" Targ Oncol (2017) 10.1007/s11523-017-0498-1

[28]

Apolo, Mortazavi, Stein, Pal, Davarpanah, Parnes, Ning, Francis, Cordes, Berniger, Steinberg, Monk, Lancaster, et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Presented at: 2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 774PD. 10.1093/annonc/mdw373.02

Metrics

20

Citations

28

References

Details

Published: Oct 23, 2017
Vol/Issue: 8(61)
Pages: 103428-103436

Authors

A

Aly-Khan A. Lalani

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

K

Kathryn P. Gray

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

L

Laurence Albiges

Institut Goustave Roussy, Villejuif, France

M

Marcella Callea

Department of Pathology, Ospedale San Raffaele, Milan, Italy

J

Jean-Christophe Pignon

Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

S

Soumitro Pal

Division of Nephrology, Boston Children’s Hospital, Boston, MA, USA

M

Mamta Gupta

Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA

R

Rupal S. Bhatt

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

D

David F. McDermott

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

M

Michael B. Atkins

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., USA

G

G.F. Vande Woude

Van Andel Research Institute, Grand Rapids, MA, USA

L

Lauren C. Harshman

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

T

Toni K. Choueiri

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

S

Sabina Signoretti

Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

Cite This Article

Aly-Khan A. Lalani, Kathryn P. Gray, Laurence Albiges, et al. (2017). Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 8(61), 103428-103436. https://doi.org/10.18632/oncotarget.21952

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression

You May Also Like